23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Butterfly Network

OmniAb Inc

Analysts say these are penny stocks to buy. Do you agree?

3 Penny Stocks To Buy According To Analysts, Targets Up To 317%

23andMe Holding Co. is a DNA testing company which has genetic information on over 12 million customers. The company announced a strong Q2 FY23, beating both revenue and earnings estimates for growth.

23andMe: Strong Genomics Quarter But Cash Burn Is Huge

Ardelyx

Y-Mabs Therapeutics Inc

Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%

23andMe Holding Co. (NASDAQ:ME ) Q2 2023 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Wade Walke - Vice President-Investor Relations Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim Chief Financial Officer & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Tiago Fauth - Credit Suisse Steven Mah - Cowen Operator Good day, and thank you for standing by. Welcome to the 23andMe's Fiscal Year 2023 Second Quarter Earnings Conference Call.

23andMe Holding Co. (ME) Q2 2023 Earnings Call Transcript

Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance

23andMe Reports FY2023 Second Quarter Financial Results

The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2022 Annual Meeting

Lucid Group

These companies haven't performed as well as I thought they would, but I don't plan to sell.

I Bought 2 SPACs That Haven't Lived Up to Expectations -- Here's Why I'm Still Holding Them

FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for confirmatory testing of the 23andMe result FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for confirmatory testing of the 23andMe result

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 (FY2023) second quarter after the market closes on Monday, November 7, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2023 Second Quarter Financial Results

CRISPR Therapeutics

They're both using unique and highly efficient approaches to developing and deploying their medicines.

2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years

Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies

23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2022 Annual Meeting

Apple

Robinhood

Gartner

TravelCenters of America

Tilray Brands

Warner Bros Discovery Inc

Reddit stocks have been so successful (or at least intriguing) that Reddit has quickly become an investing hub. The site has a huge community of investors and traders who use it as a platform for their investments.

7 Undervalued Reddit Stocks to Buy Before Wall Street Catches On

FQ1 revenue grew 9% yoy, however adjusted EBITDA loss reached $50 million and was down from the $27 million loss in the year-ago period. Full-year revenue guidance of $260-280 million was reiterated, but adjusted EBITDA loss guidance of $195-215 million remains disappointing.

23andMe: Disappointing Results Could Mean Potential Acquisition Target

Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries

Daniel Chu Joins 23andMe as Chief Product Officer

Avaya Holdings

Nutex Health Inc

Penny stocks to buy according to top money managers. The post 4 Hot Penny Stocks To Buy Now According To Top Hedge Funds appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Buy Now According To Top Hedge Funds

Latch

I own both of these companies but wouldn't put any more money into them today.

2 Ex-SPACs I Wouldn't Touch Right Now

23andMe is seeing its revenue decline as operational expenses accelerate. The company is burning cash at an alarming rate with no signs of slowing down.

23andMe: Treacherous Path To Profitability

Genetics testing provider 23andMe said its chief financial officer will leave the company next month after four years with the company. Steve Schoch notified 23andMe of his resignation earlier this week, effective Sep. 1, according to an SEC filing.

23andMe Seeks New CFO

Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ) is preparing for a major change at the executive level. Today, the firm announced that CFO Steven Schoch is planning to resign.

CFO Transition Rocks 23andMe (ME) Stock

Shares of 23andMe Holding Co. ME, +1.95% were falling more than 7% in premarket trading Friday after the DNA-testing company disclosed that Chief Financial Officer Stevem Schoch was resigning from the company. He will stop being 23andMe's "principal financial officer and principal accounting officer" as of Sept.

23andMe stock falls after company says CFO to depart

Enovix Corporation

Marqeta

Sonos

Trupanion

Investors continue to slowly move away from worries about the economy, inflation, and interest rates, sending growth stocks higher. It's not all good news and positivity, though.

Despite Some Big Losers, These Growth Stocks Are Keeping the Nasdaq Bull Market Going

23andMe Holding Co. (NASDAQ:ME ) Q1 2023 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Wade Walke - Vice President, Investor Relations Anne Wojcicki - Chief Executive Officer & Co-Founder Steve Schoch - Chief Financial Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Tiago Fauth - Credit Suisse David Lebowitz - Citi Operator Good morning, and welcome to 23andMe's Fiscal 2023 First Quarter Financial Results Conference Call. As a reminder this call is being recorded.

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q1 2023 Results - Earnings Call Transcript

First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance

23andMe Reports FY2023 First Quarter Financial Results

Trading volume is surging in the hours leading up to its quarterly financial report.

Why 23andMe Stock Jumped Higher on Monday

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday, August 8, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

News for 23andMe Stock (ME)